Novo Nordisk(US:NVO) Zheng Quan Ri Bao Wang·2025-07-16 10:50Core Viewpoint - Novo Nordisk continues to enhance its investment in China, focusing on a comprehensive industry chain strategy to better serve Chinese patients, with a mission to combat serious chronic diseases [3][4]. Group 1: Investment and Strategy - Novo Nordisk has introduced 22 innovative drugs and 11 innovative injection devices in China, addressing diabetes, obesity, and rare diseases, helping over 41 million patients by the end of 2024 [3]. - The company emphasizes a full industry chain layout, which includes commercial operations, production, and research and development [3]. Group 2: Innovation and Collaboration - At the China International Supply Chain Promotion Expo, Novo Nordisk announced new partnerships with local collaborators and launched a digital chronic disease management model, integrating online and offline resources [4]. - The company is collaborating with major internet platforms like Tencent Health, JD Health, Ping An Health, and Alibaba Health to build a digital ecosystem for chronic disease management [4]. Group 3: Sustainability Initiatives - Novo Nordisk aims for net-zero emissions across its entire value chain by 2045 and has initiated a three-year environmental management plan focusing on waste management and carbon reduction [5]. - The company has signed a multi-party agreement with leading firms in the medical field to utilize renewable energy in China, promoting green electricity transformation in the pharmaceutical industry [5].